Cas:16083-32-2 (2H12)Coronene manufacturer & supplier

We serve Chemical Name:(2H12)Coronene CAS:16083-32-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

(2H12)Coronene

Chemical Name:(2H12)Coronene
CAS.NO:16083-32-2
Synonyms:Chrysene,perdeutero;coronene-d12;chrysene-d12;(H)Coronene;Coronene-d;Perdeuterocoronen;Dodecadeuterio-coronen;dodecadeuterio-chrysene;dodecadeuterio-coronene
Molecular Formula:C24D12
Molecular Weight:312.426
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:525.6±17.0 °C at 760 mmHg
Density:1.5±0.1 g/cm3
Index of Refraction:2.140
PSA:
Exact Mass:312.169220
LogP:7.38

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like Chrysene,perdeutero chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,dodecadeuterio-coronene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Coronene-d Use and application,Dodecadeuterio-coronen technical grade,usp/ep/jp grade.


Related News: The FDA said its decision allows for the J&J doses to be used in the United States or exported. T (2H12)Coronene manufacturer In that group, the vaccine slowed brain decline by around 30% in two different clinical and functional tests, Novak said. (2H12)Coronene supplier Though Innova previously applied for a regulatory green light, the test has not been authorized or approved by the FDA for use in the U.S.—however, during inspections of the company’s California facilities in March and April, FDA investigators said they found the test was already being sold and distributed. (2H12)Coronene vendor The foundational patent, which expires in 2034, is owned by MSK and is licensed exclusively to Fate Therapeutics for all human therapeutic uses. (2H12)Coronene factory In that group, the vaccine slowed brain decline by around 30% in two different clinical and functional tests, Novak said.